logo-loader
viewVentriPoint Diagnostics Ltd.

Ventripoint says Johns Hopkins doctor cited VMS+ heart analysis system’s clinical feasibility at Milan conference

Dr Shelby Kutty gave a presentation on a study conducted at the University of Nebraska Medical Center Children's Hospital

An illustration of the cardiovascular system
Ventripoint says its system provides a cost-effective approach to volumetric measurements of all four heart chambers

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCMKTS:VPTDF) said Friday that a Johns Hopkins doctor cited the clinical feasibility of the company’s VMS+ 3.0 heart analysis system at a cardiovascular imaging conference in Milan.

The Toronto-based medical care device company said in a press release that Dr Shelby Kutty recently gave a presentation on a study of the system at EuroEcho 2018. The study was conducted at the University of Nebraska Medical Center Children's Hospital, according to Ventripoint.

READ: VentriPoint Diagnostics reveals that University of Chicago will assess its heart analysis system

"This study presented at EuroEcho 2018 demonstrates the clinical feasibility of quantifying right and left ventricular volumes and function using VMS+ on two- and three-dimensional images acquired from multiple cardiac ultrasound systems,” Shutty said in a statement.

More than 4,200 people attended the conference, according to Ventripoint.

The response to the system at EuroEcho 2018 indicates a significant need for a cost-effective and accurate approach to volumetric measurements of all four chambers of the heart, according to Mehran Mehrtash, vice president for worldwide distributor sales at Ventripoint.

“The VMS+ technology sets us apart and can make a valuable difference in patient outcomes," Mehrtash said.

The system is not yet available for commercial sale and is for investigational use only, according to Ventripoint.

Shares climbed C$0.01 to C$0.17 in Thursday’s Canadian trading.

Last month, the company told investors that the University of Chicago's medical center was preparing to study the VMS+ system.


Contact Dennis Fitzgerald at [email protected]
 

Quick facts: VentriPoint Diagnostics Ltd.

Price: 0.075 CAD

TSX-V:VPT
Market: TSX-V
Market Cap: $5.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VentriPoint Diagnostics Ltd. named herein, including the promotion by the Company of VentriPoint Diagnostics Ltd. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Ventripoint Diagnostic focussing on sales in 2020 as they...

Ventripoint Diagnostics (CVE:VPT-OTCQB: VPTDF) Executive Chairman and Acting CEO Dr George Adams sat down with Steve Darling from Proactive in Vancouver with news the company has 11 purchase orders in for their echocardiogram system that provides cardiac measurements. Adams telling Proactive...

on 20/2/20

2 min read